AI is rapidly generating a vast number of potential drug candidates, but a significant bottleneck remains in verifying which ones are viable. While Google DeepMind's recent breakthroughs in protein structure prediction have accelerated discovery, the process of characterizing these candidates for testing and production has not kept pace. Addressing this gap, 10x Science, a startup founded in December 2025, has announced a $4.8 million seed funding round led by Initialized Capital, with additional backing from Y Combinator, Civilization Ventures, and Founder Factor. The company was established by David Roberts, Andrew Reiter, and Vishnu Tejas. Roberts and Reiter are biochemists who previously collaborated in the Stanford lab of Nobel laureate Dr. Carolyn Bertozzi, while Tejas brings expertise in computer science and AI. The founders identified a critical issue in biopharma: while prediction tools can generate endless drug ideas, every candidate must pass through a rigorous characterization process to be validated. For biologic drugs, which are produced in living cells to target specific diseases, understanding protein structure is essential. Currently, the most accurate method for assessing molecules is mass spectrometry. However, this technique generates complex data that requires significant time and specialized expertise to interpret. 10x Science aims to solve this by combining deterministic algorithms rooted in chemistry and biology with AI agents capable of interpreting spectrometry data. The team spent considerable effort training these models to ensure their analyses are traceable, a requirement for regulatory compliance in the pharmaceutical industry. Early users have shown promise in the platform's capabilities. Matthew Crawford, a scientist at Rilas Technologies, a firm that performs chemical analyses for clients, reported that 10x Science significantly speeds up his work. He noted that the model surprised him with its ability to explain its conclusions and adapt to different types of molecules without extensive programming. Unlike other AI tools that may over-promise, Crawford observed that 10x Science makes reasonable assumptions, attributing this reliability to the deep domain expertise of its creators. The startup plans to use the new funding to hire engineers and refine the model while expanding its customer base, which currently includes major pharmaceutical companies and academic researchers. The founders envision a future where the platform offers a new definition of molecular intelligence by combining protein structure data with other cellular information. For investors, 10x Science represents a stable opportunity in the biotech sector. Unlike traditional drug development models, which depend on specific products winning regulatory approval, 10x offers a software-as-a-service platform that pharmaceutical companies must subscribe to monthly to process their candidate pipelines. By automating the interpretation of complex scientific data, 10x Science hopes to lower the barrier to entry for researchers who lack the resources or time to deploy advanced mass spectrometry techniques. This could allow teams to quickly obtain necessary data without getting bogged down in technical complexities, accelerating the overall pace of drug discovery.